1. ALLA AKTIER
  2. NYHETER
  3. DEVYSER DIAGNOSTICS

Devyser Diagnostics

Nyheter Devyser Diagnostics Nyheter alla bolag

Invitation to audiocast for Devyser’s Q1 report 2025

On Tuesday April 29 at 11:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its Q1 2025 report (which will have been published earlier on April 29 at 10:00 a.m. CET). 
 
The presentation will be held in English.  
 
If you wish to participate via webcast, please use the link below. 
https://devyser-diagnostics.events.inderes.com/q1-report-2025  

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference. https://conference.inderes.com/teleconference/?id=5004503  

Speakers: Interim CEO Fredrik Dahl, CFO Sabina Berlin and CCO Theis Kipling 

For more information, please contact:
Fredrik Dahl, interim CEO 
Email: ir@devyser.com
Telephone: +46 8 562 158 50
 
Sabina Berlin, CFO 
Email: ir@devyser.com 
Telephone: +46 8 562 158 50

About Devyser
Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB. 

For more information, visit www.devyser.com. 

Attachments
Invitation to audiocast for Devyser’s Q1 report 2025

Datum 2025-04-23, kl 10:00
Källa MFN
Bifogade filer
Invitation to audiocast for Devyser’s Q1 report 2025
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!